Skip to main content
. 2021 Oct 25;12:686876. doi: 10.3389/fphar.2021.686876

FIGURE 3.

FIGURE 3

Network diagrams of comparisons on all outcomes in this network meta-analysis. (A) Comparisons on dermatologic and endocrine irAEs in patients with advanced NSCLC. (B) Comparisons on pneumonitis in patients with advanced NSCLC. (C) Comparisons on colitis and hepatitis in patients with advanced NSCLC.(The circles represent treatment regimens and the size of each circle represents the number of participants, while the yellow line represents double-blind RCTs and the green is not blind.)